| Literature DB >> 29045135 |
Mingsheng Xie1, Hui Zhao1, Qisong Liu2, Yujia Zhu3, Feng Yin1, Yujie Liang1, Yanhong Jiang1, Dongyuan Wang1, Kuan Hu1, Xuan Qin1, Zichen Wang4, Yujie Wu5, Naihan Xu6, Xiyang Ye7, Tao Wang5, Zigang Li1.
Abstract
Direct inhibition of the protein-protein interaction of ERα and its endogenous coactivators with a cell permeable stabilized peptide may offer a novel, promising strategy for combating ERα positive breast cancers. Here, we report the co-crystal structure of a helical peptide stabilized by a N-terminal unnatural cross-linked aspartic acid (TD) in complex with the ERα ligand binding domain (LBD). We designed a series of peptides and peptide 6 that showed direct and high-affinity binding to ERα with selective antiproliferative activity in ERα positive breast cancer cells. The co-crystal structure of the TD-stabilized peptide 6 in complex with ERα LBD further demonstrates that it forms an α helical conformation and directly binds at the coactivator binding site of ERα. Further studies showed that peptide 6W could potently inhibit cellular ERα's transcriptional activity. This approach demonstrates the potential of TD stabilized peptides to modulate various intracellular protein-protein interactions involved in a range of disorders.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29045135 DOI: 10.1021/acs.jmedchem.7b00732
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446